In that study a different manufacturing protocol with cell expansion in IL-2 was used and all patients received preconditioning chemotherapy, however, similar outcomes of variable expansion, limited persistence and no long-term tumor responses13 were observed as in our study. The gene discussed is IL2; the disease is neoplasm.